Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Tranylcypromine + Tretinoin |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tranylcypromine | Parnate | Dl-Tranylcypromine | KDM1A Inhibitor 15 | Parnate (tranylcypromine) is a monoamine oxidase inhibitor (MAOI) that also inhibits Kdm1a (Lsd1), which may lead to inhibition of stem cell growth through epigenetic regulation (PMID: 26748182). |
Tretinoin | Vesanoid | Aberel|Aknoten|Avita|Renova|Retin-A|all-trans retinoic acid|Vitamin A Acid|ATRA | Vesanoid (tretinoin) is a form of retinoic acid, which binds to retinoic acid receptors and activates downstream signaling, potentially inducing cell differentiation and subsequently, apoptosis (PMID: 11704842). Vesanoid (tretinoin) is FDA approved for patients with acute promyelocytic leukemia harboring PML-RARA (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02273102 | Phase I | Tranylcypromine + Tretinoin | Phase 1 Study of TCP-ATRA for Adult Patients With AML and MDS (TCP-ATRA) | Completed | USA | 0 |